medlive.cn Medlive Technology Co., Ltd. 醫脈 通 科 技 有 限 公 司 (Incorporated in the Cayman Islands with limited liability) ( 於開曼群島註冊成立的有限責任公司) Stock Code 股份代號 : 2192 INTERIM REPORT 中期報告 2024 Contents 目錄 Corporate Information | --- | |-----------------------------------------------------------------------------------------------------------------------------------------------| | | | 公司資料 | | Business Overview and Outlook 業務概覽及展望 | | Management Discussion and Analysis 管理層討論與分析 | | Unaudited Interim Condensed Consol ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price range of HKD 10.38 to 10.38 [8] Core Views - The company achieved revenue of RMB 243 million in H1 2024, a YoY increase of 40.3%, and net profit attributable to shareholders of RMB 147 million, a YoY increase of 48.6% [1] - Adjusted net profit attributable to shareholders, excluding interest income, was RMB 52 million, a YoY increase of 40.1% [1] - The company's platform, Yimaitong, has nearly 7 million registered users, including over 4 million licensed physicians, covering 88% of licensed physicians in China [2] - Monthly active users (MAU) reached 2.5 million, a YoY increase of 13.6% [2] Business Analysis Platform Performance - Yimaitong's high physician coverage and user activity provide a solid foundation for precision marketing and intelligent patient management solutions [2] - The number of participating patients reached 457,000, a YoY increase of 46.9%, and the number of cooperating physicians reached 134,000, a YoY increase of 50.6% [2] Revenue Breakdown - Precision marketing and enterprise solutions revenue reached RMB 226 million, a YoY increase of 42.7%, with 158 medical clients, a YoY increase of 27.4% [2] - Medical knowledge solutions revenue was RMB 8.422 million, a YoY increase of 4.5%, driven by user growth [2] - Intelligent patient management solutions revenue was RMB 9.381 million, a YoY increase of 27.7% [2] Cost and Efficiency - Gross margin remained stable at 60.5%, slightly down by 0.1 percentage points YoY [2] - Sales expense ratio and management expense ratio (excluding R&D) decreased by 2.4 and 3.8 percentage points YoY, respectively, due to economies of scale [2] - R&D expenses as a percentage of revenue increased by 1.9 percentage points YoY, mainly due to investments in large model product development [2] Financial Forecasts - Revenue is expected to grow to RMB 541 million in 2024, RMB 712 million in 2025, and RMB 928 million in 2026, with YoY growth rates of 31.4%, 31.5%, and 30.4%, respectively [3] - Net profit attributable to shareholders is forecasted to be RMB 267 million in 2024, RMB 284 million in 2025, and RMB 304 million in 2026, with YoY growth rates of 10.3%, 6.2%, and 7.0%, respectively [3] - The company's P/E ratio is expected to be 19.3x in 2024, 18.2x in 2025, and 17.0x in 2026 [3] Historical Performance - Revenue in 2022 was RMB 314 million, growing to RMB 412 million in 2023, with YoY growth rates of 10.41% and 31.19%, respectively [5] - Net profit attributable to shareholders in 2022 was RMB 117 million, increasing to RMB 242 million in 2023, with YoY growth rates of 188.85% and 106.53%, respectively [5] - ROE (attributable to shareholders) improved from 2.67% in 2022 to 5.27% in 2023 [5]

业绩简评 2024 年 8 月 27 日，公司披露 2024 年度中期业绩：公司 24H1 实 现营收 2.43 亿元，同比增长 40.3%；实现归母净利润 1.47 亿元， 同比增长 48.6%；剔除利息收入等的调整后归母净利润为 0.52 亿 元，同比增长 40.1%。 经营分析 医脉通平台用户数及活跃度持续提升，注册用户数近 700 万人， 其中执业医师数超过 400 万人，覆盖全国执业医师的 88%；平台 月活量达到 250 万人，同比增长 13.6%。较高的医师覆盖率和用 户活跃度为公司开展精准营销及智能患者管理解决方案提供了坚 实的基础。 分业务而言，精准营销及企业解决方案收入为 2.26 亿元，同比增 长 42.7%。线上营销方式获国内医药企业认可，报告期内公司合 作医疗客户数达 158 家，同比增长 27.4%；单产品贡献收入达 67.2 万元，同比增长 7.5%。医学知识解决方案收入为 842.2 万元，同 比增长 4.5%，主要系用户数量增长所致。智能患者管理解决方案 收入为 938.1 万元，同比增长 27.7%，累计参与患者数位 45.7 万 人，同比增长 46.9%；合作医师数达 1 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Medlive Technology Co., Ltd. 醫脈通科技有限公司 （於開曼群島註冊成立的有限責任公司） （股份代號：2192） 截至2024年6月30日止六個月的中期業績公告 財務摘要 | --- | --- | |--------------|-----------| | 日止六個月 | 同比變動* | | 2023年 | | | （未經審核） | | | | % | 收益 243,443 173,506 40.3 銷售成本 (96,114) (68,283) 40.8 | --- | --- | --- | --- | |----------------------|---------|---------|-------| | 毛利 | 147,329 | 105,223 | 40.0 | | 期間溢利 | 152,706 | 101,659 | 50.2 | | 母公司擁有人應佔溢利 ...

投资逻辑 医脉通是国内领先的在线专业医师平台。公司早年主要销售医学 工具软件，目前平台还提供医学研究最新进展、临床指南、用药 参考、业内新闻、医药视频资讯等内容，已经形成覆盖 APP、PC 端、小程序的丰富产品矩阵。公司合作国内外顶尖学术机构以保 障平台内容的专业性和及时性，并通过探索AI功能、切入医学会 议场景等方式，使得用户数量持续增长。截至 2023 年末，公司拥 有注册用户680 万人，2020-2023年CAGR达24.8%；其中执业 医师用户达400 万人，占全国执业医师总人数的87%。 公司合作日本医疗 IT 头部企业 M3，持续拓宽业务范围。公司通 过有针对性地向医生用户展示医药产品资讯，帮助医药企业实现 港币(元) 成交金额(百万元) 精准营销，相较于传统线下拜访的模式受众范围更广、传播速度 11.00 60 更快、具有更高性价比。截至2023 年末，公司覆盖客户182 家， 10.00 50 同比增长40.0%；覆盖产品达386 个，同比增长35.9%。此外， 9.00 40 公司还面向医药企业推出数字市场研究、EDC等解决方案；并提 8.00 30 供智能患者管理解决方案，帮助医药公司提 ...

Financial Performance - Revenue for 2023 increased to RMB 412,004 thousand, up from RMB 314,054 thousand in 2022[6] - Gross profit for 2023 was RMB 251,335 thousand, compared to RMB 212,741 thousand in 2022[6] - Profit for the year in 2023 was RMB 251,760 thousand, significantly higher than RMB 126,421 thousand in 2022[6] - Profit attributable to owners of the parent in 2023 was RMB 242,301 thousand, up from RMB 117,321 thousand in 2022[6] - Revenue for the year ended 31 December 2023 was RMB412.0 million, a 31.2% increase compared to the previous year[19] - Net profit for 2023 increased by 99.1% to RMB251.8 million, with a net profit margin of 61.1%, up 20.8 percentage points from 2022[19] - Adjusted net profit for 2023 was RMB271.1 million, an 86.8% increase from 2022, with an adjusted net profit margin of 65.8%, up 19.6 percentage points[19] - Revenue from precision marketing and corporate solutions grew by 29.3% to RMB372.7 million in 2023[23] - Revenue from medical knowledge solutions increased by 31.6% from RMB12.3 million in 2022 to RMB16.1 million in 2023[65][66] - Revenue from intelligent patient management solutions grew by 70.2% from RMB13.6 million in 2022 to RMB23.2 million in 2023[67][68] - Cost of sales increased by 58.6% from RMB101.3 million in 2022 to RMB160.7 million in 2023[69] - Gross profit rose by 18.1% to RMB251.3 million in 2023, but gross profit margin decreased from 67.7% in 2022 to 61.0% in 2023[69] - Other income and gains surged to RMB188.5 million in 2023, up from RMB75.7 million in 2022[69] - Selling and distribution expenses increased by 13.4% from RMB28.9 million in 2022 to RMB32.8 million in 2023[70] - Administrative expenses grew by 18.0% from RMB122.4 million in 2022 to RMB144.5 million in 2023[71][72] - The Group's profit before tax increased by approximately 87.5% from RMB135.0 million in 2022 to RMB253.1 million in 2023[73] - The Group's profit for the year increased by approximately 99.1% from RMB126.4 million in 2022 to RMB251.8 million in 2023[73] - The Group's net profit margin increased by 20.8 percentage points from 40.3% in 2022 to 61.1% in 2023[74] - Adjusted net profit for the year ended 31 December 2023 was approximately RMB271.1 million, an increase of approximately 86.8% compared to RMB145.2 million in 2022[77] - The adjusted net profit margin for the year ended 31 December 2023 was approximately 65.8%, up 19.6 percentage points from 46.2% in 2022[77] - The Group's income tax expense decreased by approximately 84.1% from RMB8.6 million in 2022 to RMB1.4 million in 2023[73] - The Group's finance costs decreased from approximately RMB0.5 million in 2022 to approximately RMB0.4 million in 2023[73] - Share-based compensation added to adjusted net profit was RMB10.4 million in 2023, compared to RMB17.2 million in 2022[76] - Fair value adjustment of contingent consideration added to adjusted net profit was RMB2.2 million in 2023, compared to RMB1.2 million in 2022[76] - Foreign exchange difference added to adjusted net profit was RMB6.8 million in 2023, compared to RMB0.3 million in 2022[76] User and Platform Growth - Medlive platform reached a record high of 6.8 million registered users, including over 4 million licensed physicians, accounting for 87% of the total licensed physicians in China[9] - Medlive's registered user base reached 6.8 million, including over 4.0 million licensed physicians, covering 87% of China's licensed physicians[11][16] - The Medlive platform achieved an average of 2.4 million monthly active users (MAUs) in 2023[16] - Medlive's platform meets physicians' needs in clinical diagnosis, professional learning, and medical research with high-quality content and tools[16] - Medlive's platform is widely recognized by Chinese physicians and medical professionals as the most popular professional medical platform[16] - The number of customers for precision marketing and corporate solutions increased by 40.0% to 182 in 2023, up from 130 in 2022[23] - The number of products covered in precision marketing solutions increased from 284 in 2022 to 386 in 2023[23] - Engaged targeted physicians increased from 627,000 in 2022 to 774,000 in 2023[23] - Paid clicks increased from 7.2 million in 2022 to 9.7 million in 2023[23] - The number of clients covered by the company's solution increased by 40.0% from 130 in 2022 to 182 in 2023[24] - The number of products covered rose from 284 in 2022 to 386 in 2023[24] - Registered physician users converted to paid clicks grew from 627,000 in 2022 to 774,000 in 2023[24] - Paid clicks increased from 7.2 million in 2022 to 9.7 million in 2023[24] - The Group's chronic disease management services platform had accumulated approximately 377,000 users and 105,000 participating physicians as of December 31, 2023[45] - The return consultation rate of patients and the average dosage and frequency of medication have increased significantly after implementing the physician-patient management solution[47] AI and Technology Integration - Medlive's self-developed AI large models for specific verticals have been successfully commercialized and applied in critical scenarios[13][14] - Medlive's AI technology enhances efficiency in patient education and academic promotion for pharmaceutical and medical device companies[13][14] - The company developed a vertical AI model in 2023, integrating healthcare industry expertise to enhance AI applications in medical translation, information search, and literature organization[17] - Medlive 3.0, an intelligent medical consulting system, was successfully commercialized, providing professional information support and improving physician loyalty and operational efficiency[18] - The company's digital tools, including decentralized clinical trial (DCT) systems and AI-equipped journal selection, enhanced clinical research efficiency[30] - The company's clinical research team has expanded significantly, leveraging digital tools such as remote intelligent clinical trial systems (DCT) and AI-assisted journal selection to enhance efficiency in clinical research processes[32] - The company embedded a literature assistant into its AI model, offering features like document summarization, interpretation, and PDF translation[40] - The company launched the eClinicalResearch platform to enhance physicians' research efficiency, including SCI manuscript submission with AI journal selection[40] - The company's eBroadcasting platform translated 70,000 videos with over 98% accuracy using large model technology[39] Strategic Investments and Acquisitions - The company capitalized on industry transformation and market opportunities, enhancing the integration of technology and healthcare[9] - Medlive's strategic investments in 2023 yielded satisfactory outcomes, enriching solutions for pharmaceutical and medical device companies[12][14] - The company acquired 60% equity interest in Beijing Medcon for RMB 100,253,400, with the consideration paid in four installments totaling RMB 90,220,000 as of 2023[92][93] - Beijing Medcon's audited net profit for 2022 and 2023 exceeded RMB 17,000,000 and RMB 19,540,000 respectively, resulting in no adjustment to the acquisition consideration[92][93] - The company acquired 50% equity interest in SCMedcon for RMB 65,000,000, with the first installment of RMB 35,750,000 already paid[94][95] - SCMedcon's sellers guaranteed a cumulative audited net profit of at least RMB 58,080,000 for the years 2023-2026, with the consideration adjustable if the target is not met[95] - The company acquired 60% equity interest in Linberg Consulting for RMB 33,930,000, with the first installment of RMB 17,000,000 already paid[97][98] - Linberg Consulting's sellers guaranteed a cumulative audited net profit of at least RMB 21,720,000 for the years 2023-2026, with the consideration adjustable if the target is not met[98] - The company plans to continue pursuing strategic investments and acquisitions to generate synergies, expand its customer base, and enhance technological capabilities[99][100] - The Group raised approximately RMB4,677 million from its global offering in July 2021, with RMB640.4 million utilized by 31 December 2023 and RMB4,036.1 million remaining for future use[86][87] - The Group's capital expenditure for 2023 amounted to approximately RMB88.2 million, primarily for acquisitions and IT equipment, compared to RMB46.0 million in 2022[89][90] Regulatory and Market Environment - Regulatory policies in the pharmaceutical industry, including volume-based procurement and medical insurance negotiations, brought new opportunities for innovative drugs and digital marketing[10] - The company is subject to evolving regulatory requirements in China, particularly in healthcare, digital healthcare, and internet-related businesses, which could adversely affect its operations[144] - The company faces high customer concentration risks, with a limited number of pharmaceutical and medical device customers contributing significantly to its revenues[141] - The company's clinical research services rely on hospitals and physicians to update healthcare data, but it cannot guarantee the accuracy, quality, or timeliness of such data[143] - The company may face claims or liabilities related to its patient recruitment service if patients incur injuries from tested drugs or devices[143] Employee and Management Structure - The Group had a total of 742 full-time employees as of 31 December 2023, with 186 in content management, 239 in platform operation and customer service, 176 in research and development, 63 in general and administration, and 78 in sales and marketing[101] - Total staff costs for the year ended 31 December 2023 were approximately RMB159.2 million, an increase from RMB152.8 million in 2022, primarily due to increased headcount in sales and platform development staff[101] - The Group provides orientation and ongoing in-house training for employees, and compensates them with base salaries, performance-based bonuses, and share incentive schemes including pre-IPO and post-IPO share option schemes and a share award scheme[101] - Ms. Tian Liping, aged 57, is the Chairwoman, CEO, and an executive Director of the Company, responsible for formulating and implementing the Group's overall development strategies and business plans[102] - Mr. Tian Lixin, aged 55, is the President, head of the Medical Information Science Research Unit, and an executive Director, responsible for overseeing and managing the Group's operations[103][104] - Mr. Tian Lijun, aged 50, is an executive Director, vice president, and deputy head of the Medical Information Science Research Unit, responsible for overseeing and managing the research, development, and innovation of the Group's products and technologies[105][106] - Ms. Zhou Xin, aged 43, is an executive Director and vice president, responsible for overseeing and managing the Group's digital marketing operations and multichannel business development in healthcare marketing[107] - Ms. Zhou Xin, aged 43, is the Executive Director and Vice President of the company, overseeing digital marketing and medical marketing with over 18 years of marketing strategy and business management experience[108] - Mr. Eiji Tsuchiya, aged 59, is a Non-Executive Director with over 37 years of experience in insurance and financial consulting, and over 17 years in the healthcare technology industry[109][110] - Mr. Tsuchiya joined M3, Inc. in August 2006 and currently serves as an Executive Director of M3, Inc., a company listed on the Tokyo Stock Exchange (Stock Code: 2413.T)[111] - Mr. Kazutaka Kanairo, aged 46, is a Non-Executive Director with over 12 years of experience in M&A and corporate development, and over 11 years in management advisory[111] - Mr. Kanairo joined M3, Inc. in March 2014 and is currently the head of India & Southeast Asia business and director of global corporate development at M3, Inc.[111] - Mr. Richard Yeh, aged 55, is an independent non-executive Director of the company, responsible for providing independent advice to the Board[112] - Mr. Yeh served as the chief financial officer of CStone Pharmaceuticals (Stock Code: 2616) from July 2018 to April 2020[112] - Dr. Ma Jun, aged 69, is an independent non-executive Director of the company, responsible for providing independent advice to the Board[112] - Dr. Ma has been the chairman of the board of supervisors of the China Society of Clinical Oncology (CSCO) since September 2019[114] - Ms. Wang Shan, aged 50, is an independent non-executive Director of the company, responsible for providing independent advice to the Board[115] - Ms. Wang retired in September 2023 after working at Hitachi Solutions (China) Co., Ltd. from November 2022 to September 2023[115] - Mr. Xin Jiangtao, aged 47, is a vice president of the Group, responsible for the research and development and innovation of the Group's products and services[118] - Mr. Xin has over 20 years of medical software development experience[118] - Mr. Yang Liancheng, aged 45, is a vice president of the Group, responsible for executing overall development strategies and business plans of the Group[119] - Mr. Yang has over 19 years of experience in consulting and over five years of experience in the medical information technology industry[119] - Mr. Yang holds a bachelor's degree in trade and economics from Nankai University, a master's degree in finance from Peking University, and an EMBA from China Europe International Business School[120] - Mr. Xin Jiangtao, Vice President, has over 20 years of experience in medical software development and holds a bachelor's degree in Computer Science and Technology from Peking University[121] - Mr. Yang Liancheng, Vice President, has over 19 years of consulting experience and 5 years in the medical information technology industry, with degrees from Nankai University and Peking University[121] - Mr. Jiang Nan, Medical Director, has over 10 years of experience in the medical information technology industry and holds degrees in clinical medicine and psychiatry from Qingdao University and Peking University[122][123] - Ms. Liu Juan, Chief Client Officer, has approximately 16 years of experience in human resources management and holds a bachelor's degree in business administration and an MBA[124][125] - Ms. Yang Yanling, Joint Company Secretary, has experience in human resources management and holds a bachelor's degree in agriculture from Hebei North University[127] - Ms. Chu Cheuk Ting, Joint Company Secretary, has over 12 years of experience in the professional company secretarial field and is an associate member of The Hong Kong Chartered Governance Institute[129] Share Incentive Schemes - The total number of shares available for issue under the Post-IPO Share Option Scheme is 69,017,600 shares, representing 9.49% of the total issued shares as of December 31, 2023[157] - The Group has three share incentive schemes: Post-IPO Share Option Scheme, Pre-IPO Share Option Scheme, and Share Award Scheme, regulated under Chapter 17 of the Listing Rules[157] - The Post-IPO Share Option Scheme was approved on June 18, 2021, to incentivize and reward employees and directors for their contributions to the Group[157] - No share options were granted, vested, exercised, cancelled, or lapsed under the Post-IPO Share Option Scheme during the year ended 31 December 2023, and there are no outstanding share options under the scheme[163] - The total number of options and share awards available for grant under the Post-IPO Share Option Scheme and the Share Award Scheme as of 1 January 2023 and 31 December 2023 is 69,017,600, representing approximately 9.49% of the company's issued share capital[163] - The remaining life of the Post-IPO Share Option Scheme is approximately 7.5 years as of 31 December 2023[161] - The Pre-IPO Share Option Scheme has a remaining life of approximately 2.5 years as of 31 December 2023[165] - The total number of shares that may be issued upon exercise of all Pre-IPO Share Options granted under the Pre-IPO Share Option Scheme must not exceed 26,754,000 shares, representing 3.68% of the company's issued share capital and 3.71% of the weighted average number of shares in issue during the year ended 31 December 2023[165] - The exercise price per share for Pre-IPO Share Options is RMB 0.38, determined based on the company's net asset value and historical financial performance prior to listing[165] - Pre-IPO share options totaling 26,754,000 shares, representing 3.68% of the issued share capital, were granted to 62 grantees on 2 April 2021[166] - The weighted average closing price of shares before the exercise of Pre-IPO share options during 2023 was HK$7.39[168] - The Share Award Scheme, effective from 24 December 2021, allows for the issuance of up to 69,517,600 shares, representing approximately 9.56% of the total issued shares as of 31 December 2023[170] - The grant price for share awards under the Share Award Scheme is US$0.00001 per share, with vesting conditions including a minimum holding period of one year and up to 10 years[169] - The Share Award Scheme Mandate Limit can be refreshed with shareholder approval, and no individual participant can be granted awards exceeding 1% of the issued shares in a 12-month period without shareholder approval[170] - The Share Award Scheme has a remaining life of approximately 8 years as of 31 December 202

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Medlive Technology Co., Ltd. 醫脈通科技有限公司 （於開曼群島註冊成立的有限責任公司） （股份代號：2192） 截至2023年12月31日止年度的年度業績公告 | --- | --- | --- | --- | --- | |-------|---------------------------------------------------------------------------------------------------------------------|-----------------------|---------------------|------------| | | | | | | | | 財務摘要 | | | | | | | 截至 12 月 31 2023 年 | 日止年度 2022 年 | 同比變動 * | | | | （人民幣千元） | ...

Medlive Technology Co., Ltd. 醫脈通科技有限公司 (於開曼群島註冊成立的有限責任公司) (Incorporated in the Cayman Islands with limited liability) Stock Code 股份代號 : 2192 Interim Report ╈僿㕕⼔ 醫脈通科技有限公司 二零二三年中期報告 1 | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------|-------|--------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Cont ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Medlive Technology Co., Ltd. 醫脈通科技有限公司 （於開曼群島註冊成立的有限責任公司） （股份代號：2192） 2022年年報補充公告 謹請參閱醫脈通科技有限公司（「本公司」）截至2022年12月31日止年度的年報 （「2022年年報」）。除非另有界定，本公告所用詞彙與2022年年報所界定者具有 相同涵義。本公告旨在為2022年年報提供有關本公司股份獎勵計劃的補充資料。 根據股份獎勵計劃，有500,000份股份獎勵於2022年1月17日授出。股份於2022年 1月14日（即授出日期前一個交易日）的收市價為每股21.90港元。除上述500,000 份股份獎勵外，截至2022年12月31日止財政年度並無授出其他股份獎勵。 於2022年1月1日及2022年12月31日，根據股份獎勵計劃及首次公開發售後購 股權計劃的計劃授權可予授出之股份獎勵及購股權總數分別為69,517,600及 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Medlive Technology Co., Ltd. 醫脈通科技有限公司 （於開曼群島註冊成立的有限責任公司） （股份代號：2192） 截至2023年6月30日止六個月的中期業績公告 | --- | --- | --- | --- | --- | |-------|-----------------------------------------------------------------------------------------------------|---------------------------------------------------------------|----------------------|--------------| | | | | | | | | 財務摘要 | | | | | | | 截至 6 月 30 日止六個月 2023 年 （未經審核） （人 ...